Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > not too shabby
View:
Post by Gbathat on Oct 22, 2021 10:48am

not too shabby

ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors


...

She was formerly Sr. Vice President and Chief Patent Counsel at Genzyme, where she provided strategic guidance and IP advice for major commercial and research transactions and led a team responsible for the procurement, licensing, defense, and enforcement of Genzyme’s worldwide intellectual property. Upon Genzyme’s acquisition by Sanofi, Maggie became Vice President and Chief Patent Counsel of Sanofi Pasteur.
Comment by farmerjane on Oct 22, 2021 11:49am
Just trying to provide a deflection from yesterdays announcent. They have added Gavin Mallenfant chief operating officer, Dennis Chin Head of Manufacturing, Michael Grundman Senior Medical Advisor. Board of Directors have six listed but actually have eight.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities